On June 18, 2026, a new publication referencing ecallantide appeared in Advances in Therapy. The article, titled "Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks," presents a systematic literature review. The review examines trial designs, populations, and outcomes across studies of treatments for hereditary angioedema attacks.
Ecallantide is an approved therapy included within the scope of this review. The publication is indexed under PubMed ID 42313271. As a systematic literature review, the article compiles and organizes existing trial data rather than reporting new clinical results. No specific findings, efficacy conclusions, or safety outcomes from this review have been detailed here beyond its stated scope and title.
This entry reflects only the publication event itself: its title, journal, and date. No additional data from the article's content, methodology, or conclusions has been provided. Readers interested in the broader context of ecallantide, including its approved uses and regulatory status, can consult the compound overview for further information.